Credit Suisse Group raises the target on Biomarin Pharmaceutical Inc.(BMRN:NSD) to $122

Biomarin Pharmaceutical Inc Stock Forecast:

The average analyst target price for Biomarin Pharmaceutical Inc over the next 12 months is USD 123.50, according to 25 analysts. The average analyst rating is not available. Stock Target Advisor‘s analysis of Biomarin Pharmaceutical Inc suggests a slightly bullish outlook, based on 9 positive signals and 5 negative signals. The last closing stock price was USD 93.00, which represents a -6.12% change over the past week, a +2.49% change over the past month, and a +17.29% change over the last year.

Analysts Coverage Change:

Today RBC Capital Markets reiterated its “Sector Perform” rating for Biomarin Pharmaceutical Inc. and maintained a price target of $100. The rating suggests that the stock is expected to perform in line with the average performance of the overall sector. However, the price target indicates that there may be some potential upside in the stock, but not enough to warrant a higher rating.

Credit Suisse Group also updated its rating on Biomarin Pharmaceutical Inc.  maintaining an “Outperform” rating but lowering the price target to $120 from $122. An “Outperform” rating indicates that the stock is expected to perform better than the overall market. Although the price target was lowered, it still suggests that there may be some significant upside potential in the stock.

Guggenheim Securities also updated its price target for Biomarin Pharmaceutical Inc., lowering it to $120 from $125 but maintaining a “Buy” rating. A “Buy” rating suggests that the stock is expected to outperform the market. Although the price target was lowered, the rating suggests that the stock is still expected to perform well.

Robert W. Baird & Co. maintained its “Outperform” rating and raised the price target to $127 from $112, indicating that they expect significant upside potential in the stock. An “Outperform” rating suggests that the stock is expected to perform better than the overall market.

Wedbush Securities maintained its “Neutral” rating on Biomarin Pharmaceutical Inc. but lowered the price target to $69 from $74. A “Neutral” rating suggests that the stock is expected to perform in line with the market, and the lower price target indicates that they don’t see much potential for the stock to outperform.

BMRN Ratings by Stock Target Advisor

Top Trending Stocks

AVG Analyst Rating STA Analysis
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Very Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Bullish
StockTargetAdvisor
Hold
StockTargetAdvisor
Slightly Bearish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Very Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
Ad
Ad

Leave a Reply

Your email address will not be published. Required fields are marked *